(4-Isopropyl-phenyl)-(4-pyrazolo[1,5-b]pyridazin-3-yl-pyrimidin-2-yl)-amine

ID: ALA359963

Chembl Id: CHEMBL359963

PubChem CID: 6539364

Max Phase: Preclinical

Molecular Formula: C19H18N6

Molecular Weight: 330.40

Molecule Type: Small molecule

Names and Identifiers

Synonyms: GW805758X | GW805758X|pyrazolo[1,5-b]pyridazine deriv. 22|GW805758|N-(4-isopropylphenyl)-4-(pyrazolo[1,5-b]pyridazin-3-yl)pyrimidin-2-amine|BDBM8131|CHEMBL359963|HMS3303O04|HMS3305L02|EX-A4959|NSC756364|N-(4-propan-2-ylphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine|NSC-756364|UNC10112785|NCGC00241950-01|AB01092404-01|N-(4-Isopropylphenyl)-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amine|N-[4-(propan-2-yl)phenyl]-4-{pyrazolo[1,5-a]pyridazin-3-yl}pyrimidin-2-amine

Canonical SMILES:  CC(C)c1ccc(Nc2nccc(-c3cnn4ncccc34)n2)cc1

Standard InChI:  InChI=1S/C19H18N6/c1-13(2)14-5-7-15(8-6-14)23-19-20-11-9-17(24-19)16-12-22-25-18(16)4-3-10-21-25/h3-13H,1-2H3,(H,20,23,24)

Standard InChI Key:  UODXTGBFBIFREQ-UHFFFAOYSA-N

Alternative Forms

1. Parent:

   

   ALA359963

   GW805758X

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 330.40

Molecular Weight (Monoisotopic): 330.1593

AlogP: 4.05

#Rotatable Bonds: 4

Polar Surface Area: 68.00

Molecular Species: NEUTRAL

HBA: 6

HBD: 1

#RO5 Violations: 0

HBA (Lipinski): 6

HBD (Lipinski): 1

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 13.53

CX Basic pKa: 1.46

CX LogP: 4.20

CX LogD: 4.20

Aromatic Rings: 4

Heavy Atoms: 25

QED Weighted: 0.61

Np Likeness Score: -1.34

References

1. Tavares FX, Boucheron JA, Dickerson SH, Griffin RJ, Preugschat F, Thomson SA, Wang TY, Zhou HQ..  (2004)  N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3-ylpyrimidin-2-amines as potent and selective inhibitors of glycogen synthase kinase 3 with good cellular efficacy.,  47  (19): [PMID:15341487] [10.1021/jm040063i]

2. Stevens KL, Reno MJ, Alberti JB, Price DJ, Kane-Carson LS, Knick VB, Shewchuk LM, Hassell AM, Veal JM, Davis ST, Griffin RJ, Peel MR..  (2008)  Synthesis and evaluation of pyrazolo[1,5-b]pyridazines as selective cyclin dependent kinase inhibitors.,  18  (21): [PMID:18835709] [10.1016/j.bmcl.2008.09.069]

3. PubChem BioAssay data set, 

4. Compounds: GSK PKIS; Assays: Nanosyn kinase panel,  [10.6019/CHEMBL1961873]

5. Compounds: GSK PKIS; Assays: UNC Frye lab,  [10.6019/CHEMBL2007661]

6. Data associated with the publication PLoS ONE, 8(3), e57888, (2013) PMID: 23505445. Compounds: GSK PKIS; Assays: NIH NCATS, 

7. Huang Z, Wang T, Wang C, Fan Y..  (2022)  CDK9 inhibitors in cancer research.,  13  (6.0): [PMID:35814933] [10.1039/d2md00040g]

Source

Source(3):

• Scientific Literature
• PubChem BioAssays
• GSK Published Kinase Inhibitor Set